Evaluation of the Pharmacokinetics of IPX231 (L0007, C0001) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
Price : $35 *
At a glance
- Drugs IPX 231 (Primary) ; SR 45023A
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors IMPAX Laboratories
- 03 Jun 2014 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 17 Mar 2014 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 17 Mar 2014 IPX231 formulation L0012 was excluded as it became unavailable for use in the study.